We unveiled for the first time a link between ESRP1 amplification and FGFR2-IIIc high expression, through the axis ESRP1amp-FGFR2norm-FGFR2-IIIchigh, which seems to particularly determine the poor overall survival of patients with diffuse-type GC. Here, ESRP1 is linked to gastric cancer.